News

Debiopharm Group (Debiopharm) and Ipsen have reported that the 6-month sustained-release formulation of Decapeptyl (triptorelin embonate 22.5mg) has successfully completed its European decentralised registration procedure involving nine countries:

The European Medicines Agency (EMA )has granted Orphan Drug Designation to Amsterdam Molecular Therapeutics’ (AMT) gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy. Reportedly, Orphan

MeadWestvaco (MWV) has completed a year-long validation and industrialisation capital program for its line of preservative-free nasal pumps, the PFP N. It is available in outputs ranging from

The University of Iowa Pharmaceuticals (UIP) received a recommendation of approval from the Kansas city district office of FDA to manufacture and test an aseptically filled, sterile prescription

Alkermes has reported positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system

Compugen has signed a collaboration agreement with Bayer Schering Pharma (Bayer), covering the further evaluation of a Compugen discovered tumor target and its splice variants. Following an initial

OPKO Health has entered into a definitive agreement with Schering-Plough to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Reportedly, the lead product, Rolapitant recently completed

The US FDA has warned four companies to stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics (commonly known as narcotics) that are widely used to

NanoBio Corporation (NanoBio) has received an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research